According to the results from various experimental models, therapy with AAT is beneficial in preventing transplant rejection, ischemia-reperfusion injury, graft-versus-host disease, experimental autoimmune encephalomyelitis, preeclampsia, and inflamed pancreatic islets, among others (Lewis et al., 2005; Lewis et al., 2008; Grimstein et al., 2010; Gao et al., 2014). The gene discussed is SERPINA1; the disease is graft versus host disease.